Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Yoneda

Showing results (41-50 of 454) with videos related to

Pageof 46
Sort By:
Expert Opinion on Pharmacotherapy|April 3, 2020
Current and new pharmacotherapy options for non-alcoholic steatohepatitisYoshio Sumida, Masato Yoneda, Yuji Ogawa, et al.
Hepatobiliary Surgery and Nutrition|June 13, 2022
Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver diseaseMasato Yoneda, Takashi Kobayashi, Nogami Asako, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 14, 2006
[Treatment of NASH: nutritional counseling and physical exercise]Masato Yoneda, Koji Fujita, Tomoyuki Iwasaki, et al.
Clinical Journal of Gastroenterology|January 5, 2021
Lymphoepithelioma-like cholangiocarcinoma with Epstein-Barr virus infection treated by radiofrequency ablationAsako Nogami, Satoru Saito, Hiromasa Hasegawa, et al.
Digestion|January 27, 2011
Visceral obesity and the risk of Barrett's esophagusTomoyuki Akiyama, Masato Yoneda, Shin Maeda, et al.
Diabetes Research and Clinical Practice|August 19, 2007
Hepatic fat content-independent association of the serum level of gamma-glutamyltransferase with visceral adiposity, but not subcutaneous adiposityTomoyuki Iwasaki, Masato Yoneda, Satsuki Kawasaki, et al.
Journal of Gastroenterology|March 6, 2012
Thrombocytopenia is more severe in patients with chronic hepatitis C than in patients with nonalcoholic fatty liver diseaseHironori Mawatari, Masato Yoneda, Hiroyuki Kirikoshi, et al.
Journal of Pharmacological Sciences|January 16, 2007
Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancerAya Ihara, Koichiro Wada, Masato Yoneda, et al.
Nutrients|February 25, 2023
Impact of Sarcopenia on Non-Alcoholic Fatty Liver DiseaseMichihiro Iwaki, Takashi Kobayashi, Asako Nogami, et al.
Hepatobiliary Surgery and Nutrition|December 12, 2025
Assessing the risk of metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: is the Fibrosis-4 index still a reliable tool?Masato Yoneda, Takashi Kobayashi, Michihiro Iwaki, et al.
Pageof 46

Showing results (41-50 of 454) with videos related to

Sort By:
Pageof 46
Expert Opinion on Pharmacotherapy|April 3, 2020
Current and new pharmacotherapy options for non-alcoholic steatohepatitisYoshio Sumida, Masato Yoneda, Yuji Ogawa, et al.
Hepatobiliary Surgery and Nutrition|June 13, 2022
Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver diseaseMasato Yoneda, Takashi Kobayashi, Nogami Asako, et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 14, 2006
[Treatment of NASH: nutritional counseling and physical exercise]Masato Yoneda, Koji Fujita, Tomoyuki Iwasaki, et al.
Clinical Journal of Gastroenterology|January 5, 2021
Lymphoepithelioma-like cholangiocarcinoma with Epstein-Barr virus infection treated by radiofrequency ablationAsako Nogami, Satoru Saito, Hiromasa Hasegawa, et al.
Digestion|January 27, 2011
Visceral obesity and the risk of Barrett's esophagusTomoyuki Akiyama, Masato Yoneda, Shin Maeda, et al.
Diabetes Research and Clinical Practice|August 19, 2007
Hepatic fat content-independent association of the serum level of gamma-glutamyltransferase with visceral adiposity, but not subcutaneous adiposityTomoyuki Iwasaki, Masato Yoneda, Satsuki Kawasaki, et al.
Journal of Gastroenterology|March 6, 2012
Thrombocytopenia is more severe in patients with chronic hepatitis C than in patients with nonalcoholic fatty liver diseaseHironori Mawatari, Masato Yoneda, Hiroyuki Kirikoshi, et al.
Journal of Pharmacological Sciences|January 16, 2007
Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancerAya Ihara, Koichiro Wada, Masato Yoneda, et al.
Nutrients|February 25, 2023
Impact of Sarcopenia on Non-Alcoholic Fatty Liver DiseaseMichihiro Iwaki, Takashi Kobayashi, Asako Nogami, et al.
Hepatobiliary Surgery and Nutrition|December 12, 2025
Assessing the risk of metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: is the Fibrosis-4 index still a reliable tool?Masato Yoneda, Takashi Kobayashi, Michihiro Iwaki, et al.
Pageof 46